TRPX | tickerfilter.com

Fundamental analysis

32%

Profitability 33%

Dept financing 37%

Liquidity 19%

Performance 32%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0 0%

1 Month

0 0%

3 Months

0 0%

6 Months

0 0%

1 Year

0 0%

2 Year

0 0%

Key data

Stock price

$0.32

P/E Ratio

N/A

DAY RANGE

$0.32 - $0.32

EPS

$0.00

52 WEEK RANGE

$0.25 - $4.69

52 WEEK CHANGE

-$86.83

MARKET CAP

1.830 M

YIELD

N/A

SHARES OUTSTANDING

5.720 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,629,419

AVERAGE 30 VOLUME

$2,701,498

Company detail

CEO: Gilad Bar-Lev
Region: US
Website: http://www.therapixbio.com
Employees: 11
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and BrainBright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. The company was founded on August 23, 2004 and is headquartered in Givatayim, Israel.

TRPX - Therapix Biosciences Ltd. Sponsored ADR